IACP Featured in Bloomberg Law Article: "Is FDA Going Too Far in Enforcing Drug Compounding Law?"

The  International Academy of Compounding Pharmacists (IACP) was featured heavily in a Bloomberg Law article published today, "Is FDA Going Too Far in Enforcing Drug Compounding Law?" written by Bronwyn Mixter.

Article Excerpt:  "Addressing Food & Drug Administration (FDA) Guidance Documents and concerns that FDA has issued no rules for compounding but only guidance documents, which aren't legally enforceable,  IACP Executive Vice President Cynthia Blankenship says, 'Mass confusion has resulted from the usage of guidance documents, and the FDA is definitely circumventing the Administrative Procedure Act (APA) in our opinion,' The APA governs how federal agencies propose and establish regulations. IACP wants Congress to pass a bill (H.R. 2871) they say will fix these issues."

Blankenship also weighs in regarding FDA's  Pharmacy Compounding Advisory Committee (PCAC) - "IACP is concerned that FDA isn't getting enough input from pharmacies and providers as it implements the provisions of the DQSA. The DQSA created a new Pharmacy Compounding Advisory Committee (PCAC) to provide the FDA with advice on drug compounding issues, and the law stated the committee had to include a pharmacy member. But, when FDA created the committee, it designated the pharmacy member as a nonvoting member, and that's not real input.''

Please click here to view the entire Bloomberg Law article. ( Reproduced with permission from Pharmaceutical Law & Industry Report, 15 PLIR (OCT. 25, 2017). Copyright 2017 by The Bureau of National Affairs, Inc. (800-372-1033) <http://www.bna.com>)

IACP is working continuously to obtain press coverage of our efforts to protect patient access to compounded medications! We will continue to update you on articles in which we were successful in communicating our messages. Please email  iacpinfo@iacprx.org with any questions or concerns. 

As always, IACP is seeking patient stories that we can feature in our editorial efforts and communication on the Hill. Please share your stories with us and also submit to the  Partnership for Personalized Prescriptions (P3)  advocacy website  here . Please  join P3 and encourage your patients and providers to join! It really is critical to build as much advocacy support as we can for compounded medications. Thank you for making P3 a priority to join and communicate to your communities!

STAY CONNECTED: